These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34896968)

  • 1. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na
    Uthman L; Li X; Baartscheer A; Schumacher CA; Baumgart P; Hermanides J; Preckel B; Hollmann MW; Coronel R; Zuurbier CJ; Weber NC
    Biomed Pharmacother; 2022 Feb; 146():112515. PubMed ID: 34896968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
    Uthman L; Homayr A; Juni RP; Spin EL; Kerindongo R; Boomsma M; Hollmann MW; Preckel B; Koolwijk P; van Hinsbergh VWM; Zuurbier CJ; Albrecht M; Weber NC
    Cell Physiol Biochem; 2019; 53(5):865-886. PubMed ID: 31724838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE/PKC/NOX axis.
    Li X; Wang M; Kalina JO; Preckel B; Hollmann MW; Albrecht M; Zuurbier CJ; Weber NC
    Redox Biol; 2024 Feb; 69():102979. PubMed ID: 38061206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
    Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species.
    Li X; Römer G; Kerindongo RP; Hermanides J; Albrecht M; Hollmann MW; Zuurbier CJ; Preckel B; Weber NC
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34205045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
    Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
    Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.
    Spigoni V; Fantuzzi F; Carubbi C; Pozzi G; Masselli E; Gobbi G; Solini A; Bonadonna RC; Dei Cas A
    Cardiovasc Diabetol; 2020 Apr; 19(1):46. PubMed ID: 32264868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
    Uthman L; Nederlof R; Eerbeek O; Baartscheer A; Schumacher C; Buchholtz N; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
    Cardiovasc Res; 2019 Aug; 115(10):1533-1545. PubMed ID: 30649212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin decreases myocardial cytoplasmic Na
    Baartscheer A; Schumacher CA; Wüst RC; Fiolet JW; Stienen GJ; Coronel R; Zuurbier CJ
    Diabetologia; 2017 Mar; 60(3):568-573. PubMed ID: 27752710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.
    Park SH; Belcastro E; Hasan H; Matsushita K; Marchandot B; Abbas M; Toti F; Auger C; Jesel L; Ohlmann P; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2021 Mar; 20(1):65. PubMed ID: 33726768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.
    Chen S; Wang Q; Bakker D; Hu X; Zhang L; van der Made I; Tebbens AM; Kovácsházi C; Giricz Z; Brenner GB; Ferdinandy P; Schaart G; Gemmink A; Hesselink MKC; Rivaud MR; Pieper MP; Hollmann MW; Weber NC; Balligand JL; Creemers EE; Coronel R; Zuurbier CJ
    Basic Res Cardiol; 2024 Oct; 119(5):751-772. PubMed ID: 39046464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
    Uthman L; Kuschma M; Römer G; Boomsma M; Kessler J; Hermanides J; Hollmann MW; Preckel B; Zuurbier CJ; Weber NC
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1083-1094. PubMed ID: 33048256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases α-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts.
    Zhang H; Uthman L; Bakker D; Sari S; Chen S; Hollmann MW; Coronel R; Weber NC; Houten SM; van Weeghel M; Zuurbier CJ
    Front Cardiovasc Med; 2020; 7():592233. PubMed ID: 33344518
    [No Abstract]   [Full Text] [Related]  

  • 14. The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion.
    Sukhanov S; Higashi Y; Yoshida T; Mummidi S; Aroor AR; Jeffrey Russell J; Bender SB; DeMarco VG; Chandrasekar B
    Cell Signal; 2021 Jan; 77():109825. PubMed ID: 33160017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?
    Wichaiyo S; Saengklub N
    Heart Fail Rev; 2022 Nov; 27(6):1973-1990. PubMed ID: 35179683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin protective effects against cisplatin-induced acute nephrotoxicity by interfering with oxidative stress and inflammation in Wistar rats.
    Farrokh-Eslamlou N; Momtaz S; Niknejad A; Hosseini Y; Mahdaviani P; Ghasemnejad-Berenji M; Abdolghaffari AH
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Sep; 397(9):7061-7070. PubMed ID: 38643451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition.
    Chen S; Overberg K; Ghouse Z; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Biomed Pharmacother; 2024 May; 174():116477. PubMed ID: 38522235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibitor downregulated oxidative stress via activating AMPK pathway for cardiorenal (CR) protection in CR syndrome rodent fed with high protein diet.
    Yang CC; Chen KH; Yue Y; Cheng BC; Hsu TW; Chiang JY; Chen CH; Liu F; Xiao J; Yip HK
    J Mol Histol; 2024 Oct; 55(5):803-823. PubMed ID: 39190032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
    Kolijn D; Pabel S; Tian Y; Lódi M; Herwig M; Carrizzo A; Zhazykbayeva S; Kovács Á; Fülöp GÁ; Falcão-Pires I; Reusch PH; Linthout SV; Papp Z; van Heerebeek L; Vecchione C; Maier LS; Ciccarelli M; Tschöpe C; Mügge A; Bagi Z; Sossalla S; Hamdani N
    Cardiovasc Res; 2021 Jan; 117(2):495-507. PubMed ID: 32396609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress.
    Nikolaou PE; Efentakis P; Abu Qourah F; Femminò S; Makridakis M; Kanaki Z; Varela A; Tsoumani M; Davos CH; Dimitriou CA; Tasouli A; Dimitriadis G; Kostomitsopoulos N; Zuurbier CJ; Vlahou A; Klinakis A; Brizzi MF; Iliodromitis EK; Andreadou I
    Antioxid Redox Signal; 2021 Mar; 34(7):551-571. PubMed ID: 32295413
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.